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Mechanisms regulating DNA repair processes remain incompletely defined. Here, the cir-
cadian factor CRY1, an evolutionally conserved transcriptional coregulator, is identified as a
tumor specific regulator of DNA repair. Key findings demonstrate that CRY1 expression is
androgen-responsive and associates with poor outcome in prostate cancer. Functional stu-
dies and first-in-field mapping of the CRY1 cistrome and transcriptome reveal that CRY1
regulates DNA repair and the G2/M transition. DNA damage stabilizes CRY1 in cancer
(in vitro, in vivo, and human tumors ex vivo), which proves critical for efficient DNA repair.
Further mechanistic investigation shows that stabilized CRY1 temporally regulates expression
of genes required for homologous recombination. Collectively, these findings reveal that
CRY1 is hormone-induced in tumors, is further stabilized by genomic insult, and promotes
DNA repair and cell survival through temporal transcriptional regulation. These studies
identify the circadian factor CRY1 as pro-tumorigenic and nominate CRY1 as a new ther-
apeutic target.
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Prostate cancer (PCa) is the second leading cause of cancerdeath in US men1. First-line therapy for patients with dis-seminated disease targets the androgen receptor (AR), a
ligand-dependent transcription factor required for PCa development
and progression. Although androgen depletion and AR-targeted
therapies are initially effective, recurrent castration-resistant prostate
cancer (CRPC) arises for which there is no durable cure2. Notably,
CRPC remains largely AR-dependent due to aberrant reactivation of
AR through multiple distinct mechanisms that promote AR-
mediated cell proliferation, DNA repair, and tumor survival3.
Thus, there is an urgent need to develop novel strategies that
enhance and/or act in concert with AR-targeted therapy.
Toward this end, recent findings highlight the potential of
understanding and leveraging AR-dependent DNA repair. Clin-
ical AR suppression has long been utilized for radiosensitization,
and affords significant clinical benefit compared to radiation
alone4. Subsequent mechanistic investigation revealed AR reg-
ulates DNA repair factor expression (including DNAPK < enco-
ded by PRKDC > , Ku70/80, and PARP1)5–8. Functional studies
identified AR-mediated DNAPK expression as required for AR-
dependent double-strand break (DSB) repair, and identified
additional functions downstream of DNAPK important for the
metastatic process, forming the basis of an ongoing clinical trial
(NCT02833883). Furthermore, a recent clinical study showed that
tumors with pathogenic DNA repair factor alterations responded
more favorably than those with no detectable DNA repair
alterations to androgen depleting strategies9. Given the impact of
AR-dependent DNA repair processes on PCa progression, further
delineating the means by which AR regulates break resolution is
of translational importance.
Here, analyses of advanced PCa unexpectedly identified CRY1
(cryptochrome 1), a transcriptional coregulator associated with the
circadian clock10 as a tumor specific, AR-mediated, critical effector
of DNA repair that is deregulated in metastatic PCa patients and
associated with poor outcome. Several epidemiological studies
indicate that disruptions in circadian rhythm, such as jet lag, shift
work, sleep disruption, and suppression of melatonin by exposure
to light at night are all associated with increased risk of PCa, breast
cancer, and colon cancer4–8. Loss of circadian control is also
associated with poor efficacy of anticancer treatments and early
mortality among cancer patients9. First-in-field CRY1 cistrome and
transcriptome mapping identified CRY1 as a regulator of cell pro-
liferation and DNA repair processes, which was functionally con-
firmed in across PCa model systems. To assess relevance, exogenous
challenge with genotoxic stress (utilizing in vitro systems, in vivo
models, and human tumors ex vivo) revealed that AR-induced
CRY1 is further stabilized by genomic insult, after which CRY1
binds to promoters of homologous recombination (HR) factors to
regulate HR-mediated DNA damage response (DDR) in a cascad-
ing, temporal fashion inducing first the sensors/mediators of HR
followed by induction of HR effectors. Congruently, CRY1 strongly
correlated with HR gene expression in PCa. These collective find-
ings reveal that androgen-regulated CRY1 is stabilized in response
to genotoxic insult and governs rapid repair of DNA DSBs by
directly regulating HR gene expression, thus modulating genome
integrity and promoting CRPC growth. In sum, these studies
identify a novel, tumor-specific mechanism by which hormones
regulate DNA repair and are the first to delineate the molecular
framework used by CRY1 in PCa progression. Thus, these findings
identify CRY1 function as protumorigenic and nominate a new,
targetable pathway for managing advanced PCa.
Results
CRY1 is induced by androgens and associated with poor out-
come. Recent studies underscore the importance of AR-mediated
DNA repair factor regulation in PCa, yet this critical facet of AR
signaling is incompletely defined. AR regulates a vast transcrip-
tional network in response to androgen stimulation, as demon-
strated by cistrome and transcriptome mapping, and AR-
dependent DNA repair factor regulation is a major effector of
the response to DNA damage5–8. Leveraging recent insight into
genome-wide AR activity revealed that in the presence of
androgen-stimulation AR binds multiple regions within the CRY1
locus, encoding a transcriptional coregulator most well studied in
circadian regulation11–14 (Fig. 1a, Supplementary Fig. 1a). AR
binding at the CRY1 locus was conserved across the cell cycle in
PCa with no significant change in mRNA expression (Supple-
mentary Fig. 1a–b)15, indicating that these events are of relevance
in mitotically active cancer cells. Further investigation showed
that CRY1 is also induced in response to androgen stimulation in
CRPC cells (Fig. 1b), thus nominating CRY1 as an AR-regulated
gene of putative relevance to advanced disease. Strikingly, AR
binding to the CRY1 locus was enriched in both newly assessed
and archived analyses of PCa versus non-neoplastic tissues
(Fig. 1c)16. Together, these observations nominate CRY1 as a
tumor specific, AR-regulated target gene.
Circadian factors including CRY1 hold diverse functions across
multiple cancer types, with underpinning mechanisms poorly
defined10. CRY1 harbors known functions in lower eukaryotes as
an effector of both transcriptional control and resolution of UV-
induced DNA damage; this latter function manifests through
functional domains conferring photolyase activity with ~40–60%
similarity of protein structure to evolutionarily conserved
photolyases10,17,18. While CRY1 somatic alterations and gene
amplifications occur in several tumor types, (Supplementary
Fig. 1c), CRY1 is frequently amplified in PCa and CRPC
(Supplementary Fig. 1c–e) to a similar frequency of AR and key
target genes (KLK3, FKBP5) previously known to be amplified in
PCa (Supplementary Fig. 1f). Moreover, CRY1 expression is
strongly associated with metastasis and poor outcome (Fig. 1d,
Supplementary Fig. 1g). Interestingly, even when adjusting for
age, high CRY1 remained an independent prognostic variable
(HR 1.56 with a 95% CI [1.04–2.34], p= 0.029] (Fig. 1d), further
strengthening the importance of CRY1 functioning as a
protumorigenic factor in PCa. Moreover, the link between
CRY1 and aggressive disease was assessed in a large cohort of
radical prostatectomy specimens (n= 5239), wherein CRY1
positively correlated with increased genomic risk of metastasis
with a correlation coefficient of 0.07 (p= 1e−7) (Fig. 1e,
Supplementary Fig. 1g). The genomic risk of metastasis is defined
based on the Decipher test score which is a strong predictor of
metastasis. Combined, these studies implicate CRY1 induction (as
achieved by AR signaling and/or amplification of the CRY1
locus), as an effector of disease progression.
CRY1 cistrome mapping reveals interplay with oncogenic
transcription factors. Given the identification of CRY1 as an
androgen-regulated gene of cancer relevance, the mechanism
through which CRY1 influences cancer outcomes was assessed.
Genome-wide understanding of CRY1 function is poorly
understood, and in humans has been limited to a single
osteosarcoma model19. CRY1 cistrome mapping in CRPC using
a stringent cutoff identified 2551 CRY1-bound sites (Fig. 2a,
left). As expected, CRY1 bound to regulatory regions encoding
core circadian clock machinery, including PER3, PER2, CRY2,
and CRY1 itself (Fig. 2a, right), with the majority of total CRY1
binding events occurring at proximal promoters (37.9%) or
intronic regions (32.6%) (Fig. 2b). Notably, binding to genes
governing circadian function represented a minute fraction
(2.5%) of CRY1 binding events (Supplementary Fig. 2a-b),
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indicating that CRY1 holds functions in PCa distinct from
circadian gene regulation. This postulate was further under-
scored by the failure of PCa models to display circadian rhythm
patterns of gene networks. These data are the first to demon-
strate that in human cells CRY1 functions beyond circadian
control and significantly extends previous murine models,
which revealed that CRY1 functions distinctly from other cir-
cadian clock repressors (i.e., PER1, PER2, and CRY2) and
exhibits a binding pattern distinct from circadian clock acti-
vators (i.e., CLOCK and BMAL1)20–22. Given this new knowl-
edge, it was critical to assess the non-circadian functions of
CRY1 in cancer cells.
To identify CRY1 functions outside of circadian regulation,
analyses of CRY1 binding sites adjacent to transcriptional start
site (TSS) revealed enrichment for growth factor signaling, DNA
repair, and metabolic processes (Supplementary Fig. 2c), in
addition to expected circadian networks. To investigate potential
mechanisms of CRY1 function, de novo motif analysis was
assessed using a window of 50 bp adjacent to the center of
binding (Fig. 2c). In addition to motifs for NPAS (a factor known
to interact with CRY1)10,23, multiple motifs of PCa relevance
were enriched proximal to CRY1 binding, including several
factors elevated in PCa, linked with androgen-associated cancer
growth, and involved in the epithelial-mesenchymal transition
and cancer progression (e.g., FOXD2, SP2)24–27. The concept that
CRY1 binding is enriched for motifs associated with malignant
progression was further substantiated through known motif
analysis using a broad window around the center of binding
(500 bp) (Fig. 2d, Supplementary Fig. 2d–e), wherein expected
enrichment of circadian regulated factors (CLOCK, BMAL1, E-
Box) was complemented by enrichment of cancer-associated
transcription factors of PCa relevance, including several with
oncogenic activity (e.g., c-Myc, Max, USF1, SP1, ETS factors,
HIF-1α)28–34. Additional enriched motifs correspond to compo-
nents of the FoxA1/AR complex or are directly driven by AR to
promote AR signaling, cell proliferation/invasion, metabolic
rewiring, and ultimately tumor growth (Fig. 2d, Supplementary
Fig. 2d–e)35. These observed enrichments and related pathway
analyses (Supplementary Fig. 2c) provide the first insight into
genome-wide CRY1 activity in adenocarcinomas and reveal
functions beyond circadian regulation linked to oncogenic
factors.
Fig. 1 CRY1 is induced by androgens and associated with poor outcome. a AR binding sites on CRY1 in several PCa datasets, including in Barfeld et al.
2017, Takayama et al. 2018, Asangani et al. 2014, and Massie et al. 2011. Genomic traces showing AR binding sites on CRY1. b C4-2 cells in hormone-
deprived media (Veh) for 48 h and treated with 10 nM DHT for 16 h (Androgen-Stimulated). Cells were harvested for RNA (CRY1 and 18 S) and protein
(CRY1, AR, and Vinculin). c AR binding sites on CRY1 in human tissue comparing normal and tumor samples from a cohort of PCa patients in the
Netherlands from Dr. Wilbert Zwart and Pomerantz et al. 2015 dataset. d In the JHMI retrospective cohort, patient samples were split into groups based
on CRY1 expression into top 10% vs middle 80% vs low 10%. Patients with high (top 10%) CRY1 expression are associated with poor metastatic outcome.
e CRY1 expression was compared to the high Decipher 5239 prospective radical prostatectomy samples. N= 3 independent experiments. Data are
presented as mean values ± SEM and analyzed using Student’s t-test (*p < 0.05). Statistical significance was evaluated at 0.05 alpha level with
GraphPadPrism, version 8.3.1, Mac. Source data are provided in the Source Data file.
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CRY1 governs pathways critical for cell cycle regulation and
response to DNA damage. The observation that CRY1 is asso-
ciated with poor outcome in metastatic PCa, coupled with linkage
of the newly identified CRY1 cistrome to cancer-promoting
pathways, suggests that CRY1 plays roles distinct from circadian
regulation in PCa. To challenge this hypothesis, genome-wide
assessment of the CRY1-sensitive transcriptional networks were
evaluated utilizing newly generated doxycycline-regulated iso-
genic paired model systems of inducible CRY1 knockdown. As
shown, ~70% ablation of CRY1 protein was achieved after shRNA
induction (Fig. 3a, left), subsequent to which the first whole-
transcriptome analysis of CRY1 was assessed in human carcino-
mas (Fig. 3a, right), with strong consistency amongst biological
replicates (Supplementary Fig. 3a). Major transcriptional changes
were observed (2416 upregulated, 2736 downregulated genes)
after CRY1 knockdown (adjusted p-value < 0.05) indicating that
CRY1 influences large gene networks. Gene set enrichment
analysis (GSEA) (Fig. 3b, Supplementary Fig. 3b) revealed that
CRY1 governs transcriptional programs of cancer relevance,
including those involved in DNA replication, cell cycle regulation,
and multiple DNA repair processes. The biological effect of CRY1
on cell cycle progression in CRPC was assessed in multiple dis-
tinct isogenic pairs, wherein CRY1 ablation resulted in G2/M
arrest (Fig. 3c). Complementary studies were also performed
using a well-studied activator of CRY1 (KL001), which functions
by stabilizing CRY1 and preventing ubiquitin degradation36. As
shown, KL001 increased the steady state of CRY1 in all tested
CRPC model systems but did not result in measurable changes in
cell cycle (Fig. 3d). While these studies reveal a requirement of
CRY1 for cell cycle progression, heightened CRY1 protein proved
insufficient to alter cell cycle position. Thus, tumor-associated
CRY1 appears to be essential for cellular proliferation but alone is
insufficient to drive a hyperproliferative phenotype.
Conversely, investigation of transcriptome linkages to DNA
repair response revealed robust phenotypes of cancer relevance.
Given the identification of CRY1 as an AR-regulated gene (Fig. 1),
combined with the recent discoveries that AR promotes DSB
repair and the robust preclinical and clinical data demonstrating
that suppression of AR activity compromises DNA repair and
confers radiosensitization, interrogation of putative CRY1-
mediated DNA repair gene networks were prioritized. Numerous
DNA repair factor networks proved sensitive to CRY1 depletion,
including those essential for UV response, mismatch repair
(MMR), nucleotide excision repair (NER), and HR (Fig. 3b,
Supplementary Fig. 3c). These findings were unexpected, as the










































































































Fig. 2 CRY1 cistrome mapping reveals interplay with oncogenic transcription factors. a Heatmap and profile plots showing number and intensity of
binding sites. Right—Genomic traces of CRY1 binding at core circadian clock genes. b Genomic distribution analysis representing genomic binding regions.
Percent of total binding is shown in indicated regions. c De novo motif enrichment of CRY1 binding in vehicle treated C4-2 cells within 50 bp binding
window on each side of the center of binding with the cutoff of p < 10−20. d Known motif enrichments of CRY1 binding in vehicle treated C4-2 cells within
500 bp binding window on each side of the center of binding with the cutoff of p < 10−20.
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factors is NER10,37,38. To evaluate the functional consequence of
CRY1 on other DNA repair effects, genomic insults conferring
DSB (ionizing radiation, IR or Doxorubicin, DOX) were utilized
to examine changes in p21cip1 (CDKN1A) mRNA after CRY1
perturbation as a readout of DNA damage cell cycle checkpoint
induction (Fig. 3e)3,10. As expected, IR and DOX increased
p21cip1 expression in control cells of multiple CRPC backgrounds
with intact CRY1 (C4-2 shCON, 22Rv1 shCON), but this DNA
damage-induced event was significantly diminished in the
absence of CRY1 (60–75% reduction in the isogenic models).
Similar results were seen with transient transfection of siRNA
targeting CRY1 in C4-2 and 22Rv1 cells. Conversely,
CRY1 stabilization via KL001 resulted in modest upregulation
of p21cip1 levels even in untreated cells, with a 1.5–2-fold further
induction after CRY1 activation (Fig. 3f). These data identify
CRY1 as required and sufficient to induce cell cycle checkpoint
induction after DSB. Downstream analyses demonstrated the
biological relevance, as evidenced by a 1.6–1.8-fold reduction in
surviving cells after IR in CRY1-depleted cells (Fig. 3g) and
maintained cell growth after DNA damage in CRY1 activated
cells (Supplementary Fig. 3d). These findings reveal new insight
into CRY1 function as a modulator of cell cycle checkpoint
control and cell proliferation in response to DSB, and implicate
CRY1 in promoting cancer cell survival.
DNA damage stabilizes CRY1. Whereas CRY1 has been well
studied as a transcriptional coregulator important for regulation
of circadian rhythm, the protein is highly homologous (~40–60%
similarity) to evolutionarily conserved photolyases that are sta-
bilized in the presence of UV-induced DNA damage in plants and
Drosophila, and promote resolution of thymidine dimers17,33,34.
As a role for CRY1 in DNA repair in mammalian cells or after
DSB was unknown, the impact of genomic insult on CRY1
function was evaluated in CRPC. CRY1 protein levels increased as
a function of escalating doses of IR (Fig. 4a), with a 2–3-fold
induction observed 4-h post-IR, indicating that the effects of
DNA damage on CRY1 accumulation are rapid. A time depen-
dent increase in CRY1 was also observed from 0–8 h after 5 Gy
Fig. 3 The CRY1-sensitive transcriptome identifies alterations in DNA repair processes. a, c, e CRY1 expression was knocked down in C4-2-shCRY1 cells
for 72 h. a RNA-Seq analysis was performed on quadruplet samples for C4-2-shCON and C4-2-shCRY1 cells. MA plot depicts gene expression modulation
with the number of significant transcripts upregulated (top) and downregulated (bottom) in blue. b GSEA of RNA-Seq (KEGG and HALLMARKS Pathways)
identified enriched and deenriched pathways for CRY1-regulated pathways using FDR < 0.25. c Flow analysis was performed. d C4-2 and 22Rv1 cells were
treated with 10 µM KL001 at Day 0 and harvested for flow analysis. e After CRY1 was knocked down, cells were treated with 5 Gy IR for 4 or 24 h. f C4-2
and 22Rv1 cells were treated with 10 µM KL001 for 6 and 24 h, respectively. g C4-2-shCRY1 and 22Rv1-shCRY1 cells were treated with 5 Gy IR at Day 0
and harvested at indicated days for Pico Green to assess relative growth. N= 3 independent experiments. Data are presented as mean values ± SEM and
analyzed using two-way Anova (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). Statistical significance was evaluated at 0.05 alpha level with
GraphPadPrism, version 8.3.1, Mac. Source data are provided in the Source Data file.
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IR, wherein protein levels peaked (Fig. 4b). Similar results were
seen after DOX treatment (Fig. 4c). These observations demon-
strate that CRY1 is rapidly enriched after genomic insult, sug-
gesting mechanistic regulation of the protein by post-translational
mechanisms.
The effects of DNA damage on CRY1 stability were further
compared to those in cells treated with CRY1 activator KL001 in
the absence of DNA damage. As shown (Fig. 4d), KL001 stabilized
CRY1 and caused a 1.5–2-fold increase in protein within 6 h,
similar to the induction and timing observed after DNA damage
(Supplementary Fig. 4a–b). Importantly, basal CRY1 protein
expression was higher in 22Rv1 cells than C4-2 cells, which likely
accounts for the larger fold increase in protein expression
depicted in C4-2 cells (Fig. 4e). To discern if DNA damaged-
induced CRY1 stabilization is also attributed to post-translational
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Fig. 4 DNA damage results in CRY1 stabilization. a C4-2 and 22Rv1 cells were treated with increasing doses of IR for 4 h. b C4-2 and 22Rv1 cells were
treated with 5 Gy IR for the indicated times. c C4-2 and 22Rv1 cells were treated with 10 nM Doxorubicin (DOX). d C4-2 and 22Rv1 cells were treated with
10 µM KL001. e C4-2 and 22Rv1 cells were treated with 10 µM KL001 for 6 and 24 h, respectively. a–e Cells were harvested; protein expression of CRY1
and Vinculin was analyzed and quantified using ImageJ. f C4-2 and 22Rv1 cells were treated with 1 µM MG132 and 5 Gy IR or pretreated with 1 µM MG132
for 4 h and then treated with 10 nM DOX. Cells were harvested; protein expression of CRY1 and Vinculin was analyzed using ImageJ (*p < 0.05 for last
timepoint compared to their respective control without MG132 treatment). g C4-2 xenografts were treated with control or 4 Gy IR and harvested after
20–30 days for CRY1 IHC analysis. Scale bar 250 µm. h PDE PCa tissue was treated with 0.5 Gy IR. Tissue was harvested at 2 days for CRY1 IHC analysis.
Scale bar 250 µm. N= 3 independent experiments. Data are presented as mean values ± SEM and analyzed using two-way Anova (*p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001). Statistical significance was evaluated at 0.05 alpha level with GraphPadPrism, version 8.3.1, Mac. Source data are
provided in the Source Data file.
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CRY1 were performed after genotoxic insult, using KL001 as
comparison. As shown, use of proteasome inhibitor MG132, to
prevent protein degradation and examine stability of CRY1
expression resulted in a significant (1.8–2 fold) increase of CRY1
in the presence of DNA damage (Fig. 4f, Supplementary
Fig. 4c–d). Conversely, cycloheximide to examine the half-life
of CRY1 did not result in any significant change after genotoxic
insult (Supplementary Fig. 4e–f). These findings strongly support
the conclusion that CRY1 is activated by stabilization after DNA
damage, similar to that observed with the known CRY1
activator KL001.
To assess CRY1 regulation in vivo and gain insight into
potential clinical relevance, subsequent studies examined the
impact of DNA damage on CRY1 regulation in CRPC xenografts.
As shown, tumors treated with 4 Gy IR have increased CRY1
protein expression (Fig. 4g). Complementary studies using
primary ex vivo patient-derived explants of human PCa were
performed as previously described39–41 in the presence of 0.5 Gy
IR for 48 h (Fig. 4h). Similar to in vitro and in vivo studies, CRY1
protein increased ex vivo in response to IR treatment in primary
human tissue (Fig. 4h). Combined, multiple models of CRPC
(in vitro, in vivo) and ex vivo irradiation of primary human
tumors strongly indicate that a proximal response to DNA
damage is CRY1 stabilization. Given the strong link between
CRY1 and poor outcome in this disease type, these observations
prompted deeper investigation into the molecular consequence of
CRY1 function.
CRY1 modulates DNA repair factor expression and homo-
logous recombination. Given the clinical observations that CRY1
is upregulated in PCa and associated with poor outcome (Fig. 1),
combined with molecular observations that the protein induces
gene networks of importance for DNA repair (Figs. 2, 3) and is
stabilized after DNA damage (Fig. 4), computational strategies
were employed to integrate cistrome and transcriptome analyses,
with the goal of identifying the mechanism(s) of action by which
CRY1 modulates the response to DNA damage. Initially using a
guilty-by-association approach, the identified CRY1-responsive
transcriptome (Fig. 3, defined as significantly (p < 0.05) altered
genes after CRY1 knockdown) was integrated with the CRY1
cistrome (defined as genes with significant CRY1 binding within
the TSS (n= 1929), Fig. 2a). This stringent analysis resulted in
750 genes likely to be directly regulated by CRY1. This dataset
was subsequently compared to previously curated and published
DNA repair pathways available on MSigDB (Supplementary
Fig. 5a), which were grouped into known genes involved in HR,
MMR, NER, BER (base excision repair), and NHEJ (non-
homologous end joining) (Supplementary Fig. 5b) to establish the
categories of DNA repair factors under CRY1 regulation (Fig. 5a).
These analyses revealed widespread and potentially critical roles
for CRY1 in regulating factors associated with HR (62% of CRY1-
regulated genes), MMR (53%), BER (46%), NER (39%), and
NHEJ (14%). Significant effects were associated with HR, sug-
gesting that CRY1 is required for expression of major HR factors,
including RAD51, BRCA1, BRCA2, XRCC3, and CHEK1. The
capacity of CRY1 to alter HR gene expression was validated in
additional CRPC models (Fig. 5b). These findings provide the
first evidence that CRY1 modulates factors associated with HR,
thus regulating response to DNA damage and enhances tumor
aggressiveness through these mechanisms.
Given these observations, the impact of CRY1 on HR-mediated
DNA repair was assessed in functional assays. Initially, a well-
established mammalian reporter cell line (U2OS-DR-GFP) was
used to measure HR efficiency42–44, wherein HR is evidenced by
restored GFP expression (Fig. 5c, top). As shown, CRY1 ablation
significantly decreased HR efficiency (3.9-fold reduction), similar
to that observed after ATM inhibition (4.6-fold reduction) or
BRCA1 knockdown (8.6-fold reduction) (Fig. 5c, Supplementary
Fig. 5c). Conversely CRY1 activation (KL001) trended to an
increase in HR efficiency. These findings nominate CRY1 as a
positive effector of HR. To assess impact in PCa, CRY1 depletion
or CRY1 stabilization (KL001) strategies were employed and cells
were challenged by genotoxic insult (IR or DOX). As expected,
ATM and CHK2 mRNA increased in response to insult, but this
induction was blunted after CRY1 knockdown; conversely, KL001
induced ATM and CHK2 mRNA after DNA damage (Fig. 6a).
Use of siRNA to target CRY1 in C4-2 and 22Rv1 cells resulted in
similar outcomes (Supplementary Fig. 6a). Concordant changes
in ATM and CHK2 protein were enhanced after insult-induced
DNA damage and reduced as a result of CRY1 depletion (Fig. 6b,
Supplementary Fig. 6b).
To assess the impact of CRY1-mediated HR factor regulation
on DNA repair, resolution of DSBs after CRY1 manipulation was
quantified via γH2AX and RAD51 foci (Fig. 6c, d, Supplementary
Fig. 6c–e). As expected, γH2AX and RAD51 foci were induced
rapidly after IR and resolved in control cells by 24 h. However,
this process was markedly delayed in CRY1-depleted CRPC cells,
consistent with impaired HR function. By contrast, CRY1
induction, as is observed in human tumors (Fig. 1), accelerated
time to resolution of DNA breaks (Fig. 6d, Supplementary
Fig. 6e). Together, these results reveal unexpected roles for CRY1
as a critical regulator of HR-mediated repair in CRPC, manifested
through regulation of HR factor expression.
CRY1 temporally modulates homologous recombination factor
expression. Given these findings, the mechanistic underpinnings
of CRY1-mediated HR regulation were further considered. CRY1
did not colocalize with γH2AX foci, indicating that the role of
CRY1 is likely upstream of repair (Supplementary Fig. 7a). As
HR-mediated repair consists of sensors/mediators (MRE11 and
RAD50), transducers (ATM), activators/adaptors (RAD51,
XRCC3, and POLD2), and ultimately effectors (CHK2 and
γH2AX) to resolve DSBs3, the contribution of CRY1 to regulation
of these factors was investigated. As expected, based on integra-
tion of cistrome and transcriptome data (Fig. 5), CRY1 knock-
down decreased mRNA expression of ATM, MRE11A, RAD50,
RAD51, XRCC3, and POLD2 (Fig. 7a, Supplementary Fig. 7b).
Congruently, ChIP-qPCR using binding sites informed by the
cistrome mapping (Fig. 2) revealed increased CRY1 binding at
DNA repair sensors at 30 min post-IR treatment, which was
diminished after 4 h, suggestive that CRY1 function occurs
rapidly after DNA damage (Fig. 7b, Supplementary Fig. 7c–d).
Subsequently, downstream HR components (XRCC3 and
POLD2) emerged at later timepoints (4-h post-IR treatment),
thus revealing CRY1-mediated temporal control of HR factor
expression. Identification of CRY1 as an effector of HR gene
induction is further substantiated by the observation that
CRY1 stabilization via KL001 resulted in increased ATM,
MRE11A, RAD50, and XRCC3 expression, or conversely, sig-
nificant attenuation after CRY1 depletion (Fig. 7c, Supplementary
Fig. 7e). Interestingly, the binding of CRY1 to these key DNA
repair factors (MRE11A, ATM, POLD2, and XRCC3) and
another circadian component (CRY2) was not dependent on
hormone stimulation (Supplementary Fig. 7f). CRY1 significantly
bound to these sites in hormone depleted (CDT) and androgen
treated (DHT) conditions, supporting an independent role of
CRY1 as a protumorigenic factor. Clinically, a robust association
between CRY1 and ATM, MRE11A, or RAD50 was observed in
metastatic CRPC (Fig. 7d, Supplementary Fig. 7g), consistent with
the evidence gleaned herein using a breadth of in vitro systems,
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in vivo xenografts, and primary human tumors. Combined, these
findings identify CRY1 as a tumor specific, AR-induced effector
of poor outcome in PCa and identify entirely new functions of
CRY1 to temporally control HR and the response to genomic
insult.
Discussion
Recent observations that DNA repair alterations are highly pre-
valent in aggressive PCa and predict for poor outcome highlight
an urgent need to discern the mechanisms that regulate the DNA
repair process. Studies herein identify an unexpected, temporally
modulated mechanism of DSB repair regulation, mediated by
tumor-specific, AR-mediated induction of the CRY1 transcrip-
tional regulator. Key findings demonstrate that: (i) CRY1 is
induced by androgens in a tumor-specific manner; (ii) CRY1
induction is mediated in PCa by both AR and amplification of the
CRY1 locus; (iii) CRY1 cooperates with oncogenic transcription
factors known to induce aggressive PCa; (iv) CRY1 governs
pathways critical for cell cycle regulation and the response to
DNA damage through transcriptional regulation; (v) DNA
damage stabilizes CRY1 (vi) CRY1 is a direct and temporal
modulator of DNA repair factor expression, initially inducing
sensors of DSBs, mediators of HR, and downstream HR factors in
sequence; and (vii) CRY1 is strongly associated with HR factor
expression and poor outcome in human disease. These studies are
the first to delineate the molecular framework used by CRY1 to
enhance cancer progression and nominate CRY1-DNA repair
pathways as a potential node for therapeutic targeting in late stage
disease.
The present study reveals the first genome-wide insight into
CRY1 function in human carcinomas and provides the basis to
discern the molecular underpinnings(s) by which CRY1 impacts
cancer outcomes. A central finding is that CRY1 regulates gene
expression far beyond that associated with circadian rhythm.
Analysis of the PCa CRY1 cistrome revealed the prominence of
CRY1 binding beyond genes governing circadian rhythm with
only 49 of the 1929 (2.5%) CRY1-bound genes associated with
circadian function (Supplementary Fig. 2a–b), further empha-
sizing the concept that CRY1 functions beyond the canonical
circadian clock. This premise is supported by previous CRY1
analysis in circadian synchronized mouse livers, which demon-
strated that CRY1 functions distinctly from other circadian clock
repressors (e.g., PER1, PER2, and CRY2) and exhibits a binding
pattern distinct from circadian clock activators (e.g., CLOCK and
BMAL1)20–22. Moreover, in these previous mouse studies, CRY1
exhibited a unique pattern that peaked at circadian time zero (the
Fig. 5 CRY1 transcriptome and cistrome analyses identify direct regulation of DNA repair by CRY1. a Schematic describing the comparison of RNA-Seq
and ChIP-Seq datasets. Briefly, the DNA damage response transcripts regulated by CRY1 with p < 0.05 (no fold change cutoff) and DDR genes with a CRY1
binding site within a TSS of binding were identified and organized into specific DDR pathways. b CRY1 expression was knocked down in C4-2-shCRY1 and
22Rv1-shCRY1 cells for 72 h, RNA was harvested, and qPCR was performed. c CRY1 was knocked down in U20S-DR-GFP cells for 72 h via siRNA and cells
were treated with ATM inhibitor for 24 h or with 10 µM KL001 for 48 h. Cells were harvested for flow cytometry. N= 3 independent experiments. Data are
presented as mean values ± SEM and analyzed using two-way Anova (*p < 0.05, **p < 0.01, and ***p < 0.001). Statistical significance was evaluated at 0.05
alpha level with GraphPadPrism, version 8.3.1, Mac. Source data are provided in the Source Data file.
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onset of activity for diurnal organisms) unlike the other core
circadian clock genes45,46. Furthermore, these previous circadian
synced studies have reported that binding of individual circadian
transcriptional factors do not correlate with the circadian reg-
ulator’s binding phase45,46. Taken together, these observations
strongly support the notion that CRY1 has its own binding pat-
tern that extends beyond canonical circadian function. Intrigu-
ingly, these findings further support that even with the discovery
of the lack of consistent circadian rhythm patterns in the PCa
model systems utilized for this study, assessment of the non-
circadian functions of CRY1 is key to understanding drivers of
disease progression. Subsequent studies indicated that CRY1
bound to several nuclear receptors independent of other clock
proteins and functioned as co-repressors to PXR to mediate
xenobiotic metabolism in liver and kidney cells47. Thus, obser-
vations in multiple tissues identify CRY1 activities beyond
canonical circadian function, which have yet to be investigated in
human carcinomas.
Fig. 6 CRY1 promotes homologous recombination (HR)-mediated DNA damage response. a, b CRY1 was knocked down in C4-2-shCRY1 and 22Rv1-
shCRY1 cells for 72 h and cells were treated with 5 Gy IR for 4 or 24 h, respectively. C4-2 and 22Rv1 cells were treated with 10 µM KL001 for 6 and 24 h,
respectively. Cells were harvested for RNA and protein. c CRY1 was knocked down in C4-2-shCRY1 and 22Rv1-shCRY1 cells for 72 h. d CRY1 expression
was transiently overexpressed with transfection of a CRY1 plasmid for 48 h. c, d Cells were treated, fixed at the indicated timepoints, stained with γ-H2AX
and RAD51 antibodies, and imaged by confocal microscopy. Foci were counted and plotted as foci per cell. Scale bar 250 µm. N= 3 independent
experiments. Data are presented as mean values ± SEM and analyzed using Student’s t-test, one-way Anova, or two-way Anova (*p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001). Statistical significance was evaluated at 0.05 alpha level with GraphPadPrism, version 8.3.1, Mac. Source data are
provided in the Source Data file.
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In comparison to the only other analyses of CRY1 function in
humans, CRY1 appears to harbor distinct activities in carcinomas
versus sarcomas. In osteosarcoma cells, CRY1 bound primarily to
intergenic regions (49.3%) followed by intronic (28.4%) and
promoter regions (7.5%)19. Observations in PCa proved quite
distinct, in which CRY1 preferably bound to promoter (37.9%)
and intronic regions (32.6%), with only a minority in intergenic
regions (17.1%) (Fig. 2b). While the sarcoma cells studied do
harbor a circadian clock, a rather small number of clock-
controlled genes oscillated, and with low amplitude19. Herein, the
same core circadian clock genes that are rhythmically controlled
by CRY1 in osteosarcoma cells are also bound by CRY1 in PCa
(i.e., CRY1, CRY2, PER2, and PER3) (Fig. 2a) showing con-
cordance of binding across models regardless of circadian syn-
chronization. Notably, analyses of the osteosarcoma dataset
revealed conservation of at least one CRY1 binding site of
Fig. 7 CRY1 regulates HR gene expression via binding to promoters and CRY1 correlates with HR gene expression in human disease. a CRY1 was
knocked down in C4-2-shCRY1 cells for 72 h. b ChIP-qPCR was performed to examine CRY1 binding after 30mins and 4 h of 5 Gy IR treatment in C4-2
cells. Binding is plotted as percent of input. c CRY1 was knocked down in C4-2-shCRY1 cells for 72 h and cells were treated with 5 Gy IR for 4 h. C4-2 cells
were treated with 10 µMKL001 for 6 h. d Co-expression of CRY1 and either ATM,MRE11A, and RAD50mRNA in PCa tissue from publicly available data from
MSKCC (Cancer Cell 2010). eModel summarizing the findings from this study. N= 3 independent experiments. Data are presented as mean values ± SEM
and analyzed using Student’s t-test or two-way Anova (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). Statistical significance was evaluated at
0.05 alpha level with GraphPadPrism, version 8.3.1, Mac. Source data are provided in the Source Data file.
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putative impact on HR factor regulation (RAD51B). The impor-
tance of CRY1 on DNA repair in osteosarcomas has yet to be
studied. On balance, data herein reveal entirely new, protu-
morigenic functions for CRY1, beyond circadian control.
Pathway analysis, functional molecular studies, and biological
validation herein revealed that CRY1 governs a discrete network
of transcriptional programs of cancer relevance, including reg-
ulation of DNA replication, cell cycle control, and multiple DNA
repair processes. While there is some limited precedent for CRY1
in influencing cell cycle regulation10,48,49, the role of CRY1 in
transcriptional regulation of double-strand DNA repair regula-
tion was unexpected. Functional assessment herein demonstrated
that CRY1 regulates DNA DSB repair in a cascading, temporal
fashion inducing first the sensors/mediators of HR followed by
induction of HR effectors. Briefly, in response to DNA damage,
CRY1 is stabilized (Fig. 4f, Supplementary Fig. 4c–d) and directly
binds to key HR factors in a systematic manner to enhance DSB
repair (Fig. 7b, Supplementary Fig. 7c). Within 30-min post-
radiation, CRY1 binds to MRE11A, RAD50, ATM, and RAD51;
subsequently, CRY1 binds to regulatory foci of the downstream
HR factors XRCC3 and POLD2. Thus, CRY1 orchestrates the
DNA repair process through coordinated, temporal control of HR
factor expression, and subsequent functional studies demon-
strated that CRY1 is necessary for efficient repair (Figs. 6–7).
Conversely, CRY1 induction and stabilization, as observed in
human disease, enhances the HR process and is strongly asso-
ciated with poor outcome (Fig. 7e). As CRY1 harbors no inde-
pendent transcriptional transactivation domain, the
underpinning mechanisms of CRY1 function likely occur through
modulation of multiple oncogenic transcriptional factors. As
described in the previous section (Fig. 2c–d, Supplementary
Fig. 2d–e), binding enrichment was observed for a large number
of oncogenic transcription factors of established PCa relevance,
including ETS factors, basic helix-loop-helix factors, forkhead
factors, and zinc finger components. Additionally, de novo
enrichment analysis indicated that the most significantly enriched
motif for CRY1 binding was highly homologous for NPAS, which
belongs to a family of transcription factors with variable activa-
tion or repression domains that can heterodimerize or form
complexes capable of DNA binding and target gene
regulation23,50. Future studies will be directed at determining
which of these factors most influence the protumorigenic func-
tions of CRY1. Furthermore, CTCF (CCCTC-binding factor)
identified here as enriched near sites of CRY1 binding has been
previously shown to modulate HR-mediated DNA repair through
regulation of MRE11 and recruitment of CtIP, impacting double-
strand resection and overall HR efficiency51. In sum, CRY1 has a
unique binding pattern, strong potential for co-regulation with
key oncogenic factors to impact transcriptional control, and
functions beyond canonical circadian regulation to impact DNA
repair and ultimately stimulate stability and growth.
Critically, findings herein strongly link tumor-specific CRY1
induction with poor outcome and altered DNA repair processes.
Data demonstrate that CRY1 can be induced through either
amplification or by active AR signaling wherein androgen sti-
mulation leads to AR directly binding to the CRY1 locus to
induce expression (Fig. 1a–b, Supplementary Fig. 1a). AR is a key
driver of PCa, and this study identifies another avenue to pro-
mote disease progression through regulation of CRY1, which
further enhances DDR to promote genomic instability and tumor
growth. While the mechanisms by which AR specifically binds to
the CRY1 locus and induces CRY1 expression remain undefined,
these findings identify a target of AR-regulation that promotes
cancer phenotypes. Like AR itself, CRY1 is also amplified in a
subset of PCa, and these amplification events are associated with
poor outcome (Fig. 1). The impact of the CRY1 amplicon in
tumor behavior is a fertile area for future investigation, as co-
amplification in this region of 12q23 is frequently observed in
concert with adjacent genes of potential relevance to cancer.
Specifically, PARPBP (DDR factor suppressing replication stress),
ELK3 (ETS factor), POLE (DNA repair factor), and ROCK1/2
(Rho-associated kinases involved cell adhesion, motility, and
proliferation)52–55 are found in chromosomal proximity to the
CRY1 locus. In SU2C/PCF Dream Team cohort56, CRY1 ampli-
fication was present in 19 tumors, of which co-amplification
occurred with PARPBP (84%), ELK3 (68%), POLE (68%),
ROCK1 (10.5%), and ROCK2 (10.5%). The contribution of these
co-amplified events on CRY1-dependent DNA repair will be of
importance to discern. Furthermore, while the present study
established CRY1 as an upstream effector of HR, genome-wide
analyses nominated additional DDR pathways regulated by CRY1
including NHEJ. Thus, it will be worthwhile to further explore the
role of CRY1 in shifting DNA repair competencies of additional
pathways.
Finally, studies here underscore the overall clinical relevance
of CRY1 alterations in cancer. Findings here revealed a strong
association between androgen induced CRY1 and poor out-
come. These observations are critical, as androgen depletion is
standard of care for combination with radiotherapy in locally
advanced PCa to suppress AR activity, which impairs DNA
repair57–59. Furthermore, CRY1 expression strongly correlates
with HR factors identified herein as CRY1 regulated (ATM,
MRE11A, and RAD50), reinforcing the observation that CRY1
directly regulates HR gene expression to mediate DNA repair.
Thus, it will be intriguing to examine the effect of hormone-
and radiotherapy on tumors with high CRY1 expression. The
role of CRY1 in influencing the response to PARP1/2 inhibitors
should also be explored; current clinical testing illustrated the
benefit of targeting DNA repair in CRPC via PARP1/2
inhibitors60,61, and PARP1/2 inhibitors have also been shown
to result in improved responses in combination with AR-
suppressing therapeutics, irrespective of HR mutational sta-
tus62. Given that CRY1 is AR-regulated and critical for HR-
mediated DNA repair, CRY1 status may provide insight into
tumors that may respond to PARP1/2 and/or AR suppression.
Determining mechanisms to directly antagonize CRY1 function
in the clinical setting may also be an important next avenue of
investigation. Notably, the FBXL3 E3 ligase is known to prompt
CRY1 degradation downstream of AMPK63–65, and AMPK
activators are currently in clinical development66. Finally, the
concept of chronotherapy can also be considered, which may
provide a mechanism to control CRY1 expression. While
unstudied in PCa, there is significant evidence in other solid
tumor types that adjusting diurnal timing for radiotherapy can
alter outcomes10,67–70. Irrespective of mechanism employed,
the data herein provide the foundation to develop strategies for
thwarting AR-mediated CRY1 expression, DNA damage-
mediated CRY1 stabilization and/or CRY1 function in PCa as
a novel strategy for therapeutic intervention.
Taken together, studies herein reveal fundamental new
knowledge of CRY1 function in human malignancy, wherein
CRY1 expression is specifically induced in PCa progression and
associated with poor outcome. Molecular interrogation and bio-
logical assessment of CRY1 function suggest a paradigm shift by
revealing a novel mechanism of action in response to genotoxic
insult and illuminate a cascading, temporal regulation of HR
factors necessary to elicit repair and promote CRPC growth. The
present findings underscore the importance of discerning cancer-
promoting factors beyond canonical function by yielding critical
insight into androgen-regulated CRY1 function and a novel role
in DNA repair while nominating potentially impactful ther-
apeutic targets to enhance patient outcome of this lethal disease.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20513-5 ARTICLE
NATURE COMMUNICATIONS |          (2021) 12:401 | https://doi.org/10.1038/s41467-020-20513-5 |www.nature.com/naturecommunications 11
Methods
Cell culture and reagents. C4-2, 22Rv1, and LNCaP cells were purchased from
ATCC, authenticated by ATCC, and tested for mycoplasma upon thawing of cells.
All C4-2 and LNCaP derived cell lines were cultured and maintained in Improved
Minimum Essential Medium (IMEM) (Thermo Fisher Scientific, 10024CV) sup-
plemented with 5% FBS (fetal bovine serum, heat inactivated), 1% L-glutamine
(2mmol/l), and 1% penicillin-streptomycin (100 units/ml). All 22Rv1-derived cell
lines were cultured and maintained in Dulbecco’s Modified Eagle Medium (DMEM)
(Thermo Fisher Scientific, 10017CV) supplemented with 10% FBS, 1% L-glutamine,
and 1% penicillin-streptomycin. All cells were cultured at 37 °C at 5% CO2.
Generation of doxycycline-inducible cell lines. For generation of inducible
(shCON and shCRY1) cell lines, C4-2 and 22Rv1 cells were transduced with
SMARTvector Human Inducible nontargeting mCMV-TurboGFP control shRNA
or CRY1 shRNA (Dhamacon V3SH11252-225276283) lentiviral vectors. Trans-
duced cells underwent at least three rounds of antibiotic selection with puromycin.
These newly generated cell lines were deemed C4-2 shCON and 22Rv1 shCON for
the control doxycycline-inducible shRNA cell models and C4-2 shCRY1 and
22Rv1-shCRY1 for the doxycycline-inducible CRY1 shRNA knockdown cell
models.
Chromatin immunoprecipitation (ChIP)-sequencing. C4-2 cells were plated in
hormone-proficient media. ChIP was performed as previously described15. Briefly,
cells were cross-linked with 1% fresh formaldehyde for 10 mins at room tem-
perature. Chromatin was sheared to 200-700 bp using Diaganode Ultrasonicator
for 30 cycles (30 s on, 30 s off). CRY1 antibody was obtained from Dr. Michael
Brunner and generated as described19. The ChIP-Seq libraries were constructed
using the Swift BioSciences ACCEL-NGS 2 s Plus DNA Library kit with ~10 ng of
ChIP DNA. NextSeq 500 sequencer from Illumina was utilized to sequence samples
at the TJU Sidney Kimmel Cancer Sequencing Core Facility. ChIP-Seq data have
been deposited in the GEO repository under the accession number GSE144960.
Supplementary Table 1 describes the primers utilized to validate CRY1 binding
with ChIP-qPCR.
ChIP-sequencing analysis. FASTQ files were assessed for quality using FASTQC
v0.11.5. Reads were aligned to the human genome reference version hg19 using
bowtie2 v2.3.271 with default parameters. Peak calling was performed using
MACS2 v2.1.172 with combined replicates, utilizing a q < 0.05 cutoff. ChIP-Seq
binding heatmaps and profiles were generated using deepTools v2.5.773. Peak
annotation and motif analysis performed using Homer v4.10.374 using the para-
meters indicated.
Clinical sample ChIP-seq data. AR ChIP-seq data from normal prostate tissue (n
= 8) and primary prostate tumor samples (n= 8) were described first in ref. 75, and
merged with samtools. Then, the samtools view -s function was utilized to generate
merged files with comparable read numbers. Sample profiles were then plotted with
the deepTools plotProfile function73. Pomerantz et al.16 data (previously aligned
and normalized bigwig files) were downloaded and analyzed in their published
format, with deepTools used for visualization. Patient description for the Nether-
lands cohort is detailed in the Table 1 below. The description for the Pomerantz
et al.16 dataset can be found in the Supplementary Table 1 of the study16.
Patient cohort description. Tissue collected for the JHMI (Johns Hopkins) cohort
of patients who underwent RP (radical prostatectomy) between 1992–2010 at John
Hopkins Hospital with median follow-up of 108 months for the metastasis end-
point. These patients were selected as a retrospective case-cohort design study for
men who underwent radical prostatectomy at high risk and received no additional
therapy till the onset of metastasis. More details about sampling and patients are
found in the Ross et al., European Urology, 2016 study [PMID 26058959]. Addi-
tionally, the Decipher cohort is a prospectively collected cohort as part of the
routine clinical use of the Decipher test. Patients in this cohort have not reached
the metastasis endpoint yet, so we are using patients with high Decipher score as a
surrogate endpoint for metastasis. The clinical characteristics for the Decipher and
JHMI (Johns Hopkins) cohorts can be found in Table 2 below.
Co-expression analysis. Correlation analysis was performed using cBioPortal76,77
utilizing data from the studies indicated.
RNA-sequencing. C4-2 shCON and C4-2 shCRY1 cells were treated with dox-
ycycline for 3 days to knockdown expression of CRY1 in biological quadruplicate.
Following manufacturer’s instructions, RNA was extracted and purified using the
miRNeasy kit (QIAGEN). TJU Sidney Kimmel Cancer Sequencing Core Facility
performed RNA-sequencing. Briefly, TruSeq Stranded Total RNA Library Prep
Gold kit was used to construct the RNA-seq libraries. NextSeq 500 sequencer from
Illumina was utilized to sequence samples using single-end 75 bp reads.
RNA-sequencing analysis. FASTQ files were aligned using STAR v2.5.2a78–80
against the human genome (hg19). Read counts for each gene were generated using
featureCounts81 utilizing Ensembl as reference gene annotation set. Differential
gene expression data were generated using DESeq2 v1.12.482. Gene set enrichment
analysis (GSEA) was performed using HALLMARKS and KEGG gene signatures
from the Molecular Signature Database83. RNA-seq data have been deposited in
the GEO repository under the accession number GSE144961.
Flow cytometry. All C4-2- and 22Rv1-derived cells were plated at equal densities
in hormone-proficient media. Once all treatments were completed, cells were
incubated with BrdU (1:1000) for 2 h prior to harvesting. Cells were fixed and
processed as previously described84. At least 10,000 events per sample were
assessed. Analysis was performed using InCyte software (Guava) for cell cycle
profile with BrdU incorporation and PI (propidium iodide).
Gene expression analysis. All C4-2- and 22Rv1-derived cells were plated at equal
densities in hormone-proficient media. Trizol (Invitrogen) was used to isolate RNA
and SuperScript VILO (Invitrogen) was used to generate cDNA following manu-
facturer’s instructions. PowerSybr (Fischer Scientific 43-676-59) and the ABI
Table 1 Clinical characteristics for Netherlands cohort
patient data.
Sample Gleason score Age Tumor cells percentage in
samples (%)
1 3+ 4= 7 69 70
2 4+ 4= 8 73 40
3 3+ 4= 7 67 30
4 4+ 3= 7 68 40
5 4+ 5= 9 67 60
6 3+ 4= 7 54 65
7 3+ 4= 7 62 70
8 3+ 4= 7 64 30










Total 5239 (100%) 355
Age (years) 65.5 (60, 69.2) 59 (56,64)
PSA at diagnosis
(ng/mL)
6.5 (4.8, 9.7) 8.6 (5.7,13.3)
<10 ng/mL 1886 (36%) 209 (58.9%)
10-20 ng/mL 441 (8.4%) 111 (31.2%)
>20 ng/mL 166 (3.1%) 34 (9.6%)
Gleason grade group
1 271 (5.1%) 7 (2%)
2 1769 (33.7%) 150 (42.2%)
3 1209 (23%) 66 (18.6%)
4 396 (7.5%) 35 (9.9%)
5 554 (10.5%) 97 (27.3%)
PSM
Present 2099 (40%) 102 (28.7%)
EPE
Present 2092 (40%) 238 (67%)
SVI
Present 781 (15%) 86 (24.2%)
LNI
Positive 195 (3.7%) 62 (17.5%)
Metastasis outcome NA 127 (35.8%)
High genomic risk
(Decipher)
1476 (28%) 46 (12.9%)
Median follow-up
(months)
48 [36–54] 108 [72-144]
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StepOne Real-Time PCR system were utilized in accordance with manufacturer’s
specifications to perform quantitative PCR (qPCR) analyses. The primers used are
depicted in Supplementary Table 2.
Immunoblotting. All C4-2- and 22Rv1-derived cells were plated at equal densities
in hormone-proficient media. Generation of cell lysates was described previously6.
Forty to fifty microgram of lysate was resolved by SDS-PAGE, transferred to PVDF
(polyvinylidene fluoride) membrane, and analyzed using the following antibodies
at 1:1000 dilution—CRY1 (Bethyl A302-614A), ATM (Cell Signaling Technology
(CST) 2873), phospho-ATM (Ser1981) (CST 5883 S), CHK2 (Bethyl A300-619A),
phospho-CHK2 (Thr68) (CST 2661 T), MRE11 (CST 8344 T), RAD50 (CST 8344
T), RAD51 (Abcam ab63801), XRCC3 (Novus NB100-165), and Vinculin
(Sigma–Aldrich V9264).
Proliferation assays. All C4-2- and 22Rv1-derived cells were plated at equal
densities in hormone-proficient media. Cells were treated with either IR (irradia-
tion), CRY1 activator (KL001, Sigma–Aldrich SML1032), or doxycycline, which
was refreshed every 48 h. Cell number was quantified using the Quanti-IT Pico
Green dsDNA assay kit (Thermo Fisher) at the indicated times of treatment.
Xenograft analysis. C4-2 cells were resuspended in 100 μL of 50% Matrigel (BD
Biosciences) and saline mixture followed by subcutaneous injection in athymic
nude mice (age at least 6 weeks old). Once tumors reached 150 mm3, treatment of
4 Gy IR was initiated. Mice were sacrificed at 20–30 days post-treatment, and
tumors were harvested to assess for CRY1 staining. All the mice used in this study
were male. No mice lost more than 5% of their body weight throughout the
duration of the study. The Institutional Animal Care and Use Committee (IACUC)
at Thomas Jefferson University approved all protocols for this study. Importantly,
this study has complied with all relevant ethical regulations for animal testing and
research.
Patient Derived Explant (PDE). Deidentified prostate tissues (matched non-
neoplastic and tumor) were utilized as ex vivo PDE cultures as previously
described7,39–41,85. TJU’s Institutional Review Board has reviewed this protocol and
deemed this research to follow federal regulations [45 CFR 46.102(f)]. PDE cultures
were treated with 0.5 Gy IR and harvested after 48 h for immunohistochemistry
(IHC) analyses.
Immunohistochemistry (IHC). For histological analysis from xenograft and PDE
tissue, FFPE sections were stained with CRY1 (1:250) (LifeSpan Biosciences LS-
B6955) using standard techniques previously described6.
Homologous recombination (HR) activity assay. U2OS-DR-GFP cells are a
modified osteosarcoma cell line that were generated by Dr. Jasin and were utilized
to assess HR activity as previously described43,44. Dr. Roger A. Greenberg (Uni-
versity of Pennsylvania) provided these cells that were utilized in this study. These
cell lines Cells were transfected with siCRY1 or siBRCA1 using Dharmafect 4
reagent following manufacturer’s instructions. 48 h post-transfection, ISce1 plas-
mid was transfected into cells to induce DNA breaks. Cells were treated with ATM
inhibitor (KU-55933, Sigma–Aldrich SML1109) or CRY1 Activator (KL001,
Sigma–Aldrich SML1032) for the last 16 h of the assay. Cells were harvested and
GFP positive cells were quantified via flow cytometry.
Immunofluorescence (IF). Cells were plated at equal densities on poly-L-lysine
coated coverslips and treated as indicated. The antibodies used were γH2AX
phospho-S139 (EMD Millipore 16-202 A), RAD51 (Abcam ab133534), and CRY1
(Thermo Fisher Scientific PA1-527) at 1:500 dilution. IF assay was performed as
described7. Foci were imaged utilizing Zeiss Cell Discoverer Confocal Microscope
at 40X magnification with at least five fields for each replicate. Fiji image software
was utilized to quantify foci formation and compared to control samples.
Statistics. All experiments were performed in technical triplicate with at least three
biological replicates per condition. Data are displayed as mean ± standard error of
the mean (SEM). Statistical significance (p < 0.05) was determined using Student’s
t-test, one-way ANOVA, and two-way ANOVA on GraphPad Prism Software
(version 8.3.1) as appropriate and indicated in applicable figure legends.
Study approval. The use of patient and clinical material was approved by the
ethical committees from each of the following institutes: the Sidney Kimmel Cancer
Center at Thomas Jefferson University (Pennsylvania, USA), the Department of
Radiation Oncology at the University of California at San Francisco (California,
USA), and Division of Oncogenomics in the Oncode Institute and the Netherlands
Cancer Institute (Amsterdam, The Netherlands).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The datasets generated during the current study have been deposited in public
repositories. ChIP-Seq data have been deposited in the NCBI Gene Expression Omnibus
(GEO) with the accession code GSE144960. RNA-Seq data have been deposited in the
NCBI GEO with the accession code GSE144961. Molecular Signature Database
(MSigDB) was utilized for pathway analyses. Source data are provided with this paper.
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